AFT lifts profit guidance after weak start

Hikma Pharmaceutical’s first sale of Maxigesic IV in the US delivers boost for AFT Pharmaceuticals  AFT Pharmaceuticals – the owner of the Maxigesic ibuprofen/paracetamol combination drug – has raised its operating profit guidance to $25m after a deal in the US triggered a new licensing fee.     AFT said the US licensee of Maxigesic IV,